IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.2630
+0.0011 (0.42%)
Jun 26, 2026, 4:00 PM EDT - Market closed
IGC Pharma Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, IGC Pharma stock has a consensus rating of "Strong Buy" and an average price target of $4.25. The average 1-year stock price forecast is 1,515.97% higher than the current stock price, while the lowest is $3.00 (+1,040.68%) and the highest is $5.50 (+1,991.25%).
Price Target: $4.25 (+1,515.97%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for IGC Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Dec '25 | Feb '26 | Apr '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant | Ascendiant | Buy Maintains $5.25 → $5.5 | Buy | Maintains | $5.25 → $5.5 | +1,991.25% | Jun 5, 2026 |
Financial Forecast
Revenue This Year
857.00K
from 1.27M
Decreased by -32.57%
Revenue Next Year
1.03M
from 857.00K
Increased by 20.01%
EPS This Year
-0.09
from -0.09
EPS Next Year
-0.09
from -0.09
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 857,000 | |
| Avg | 857,000 | |
| Low | 857,000 |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | -32.6% | |
| Avg | -32.6% | |
| Low | -32.6% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | -0.09 | |
| Avg | -0.09 | |
| Low | -0.09 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | |
| Avg | - | |
| Low | - |